CLAIM AMENDMENTS:

This listing of claims will replace all prior versions and listings of claims in the application:

1-41. canceled

42. (previously presented) A pharmaceutical composition comprising:

a) a therapeutically-active compound having

i) an aqueous solubility of less than about $1x10^{-4}$ molar; and

ii) a substantial binding affinity to plasma proteins where greater than about 90% of the therapeutically-active compound is protein bound in spontaneous equilibrium at room temperature; and

b) a plasma protein in controlled aggregation state;

where greater than about 98% of the therapeutically-active compound is non-covalently bound to the plasma protein.

43. (previously presented) The pharmaceutical composition of claim 42 where the composition is in solid form.

44. (previously presented) The pharmaceutical composition of claim 42 where the composition is an aqueous solution.

45. (previously presented) The pharmaceutical composition of claim 42 where the composition is a lyophilized solid.

46. (previously presented) The pharmaceutical composition of claim 42 where the therapeutically-active compound is a cytostatic, an antibiotic, a vitamin, an antiinflammatory, an analgesic, an anticonvulsant, an immunosuppressant, an antiepileptic, an anxiolytic, a hypnotic, an antifungal agent, an anticoagulant, a lipid peroxidase inhibitor, a coronary vasodilator, an antiarrythmic agent, a cardiotonic, a uricosuric, an antithrombotic, a steroid hormone, or a photo-sensitizer.

47. (previously presented) The pharmaceutical composition of claim 42 where the therapeutically-active compound is amphotericin B, an adriamicine analogue, apazone, azathioprin, bromazepam, camptothecin, carbamazepin, clonazepam, cyclosporin A, diazepam, dicumarol, digitoxin, dipyridamole, disopyramide, flunitrazepam, gemfibrozil, ketochlorin, ketoconazole, miconazole, niflumic acid, oxazepam, paclitaxel, phenobarbital, phenytoin, progesterone, propofol, ritonavir, sulfinpyrazone, suprofene, tacrolimus, tamoxifen, taxonoid, testosterone, tirilazad, trioxsalen, valproic acid, or warfarin.

48. (previously presented) The pharmaceutical composition of claim 42 where the plasma protein is a serum albumin, an immunoglobulin, a glycoprotein, an interferon, or an interleukin.

49. (previously presented) The pharmaceutical composition of claim 48 where the plasma protein is a human plasma protein.

50. (previously presented) The pharmaceutical composition of claim 48 where the plasma protein is a recombinant plasma protein.

51. (previously presented) The pharmaceutical composition of claim 42, where the therapeutically-active compound is present in a mole/mole ratio to the plasma protein within the range of 1:0.05 to 1:100.

52. (previously presented) The pharmaceutical composition of claim 47, where the therapeutically-active compound is paclitaxel, amphotericin B, camptothecin, carbamazepin, cyclosporin A, or propofol.

53. (previously presented) The pharmaceutical composition of claim 52, where the therapeutically-active compound is paclitaxel.

54. (previously presented) The pharmaceutical composition of claim 53, where the plasma protein is human serum albumin or human gamma globulin.

55. (previously presented) The pharmaceutical composition of claim 54, where the plasma protein is human serum albumin.

56. (previously presented) The pharmaceutical composition of claim 42, wherein the pharmaceutical composition is an injectable form suitable for parenteral administration.

57. (previously presented) A pharmaceutical composition prepared by a process comprising:

a) dissolving a therapeutically-active compound in a water-miscible, pharmaceutically acceptable organic solvent;

b) dissolving a plasma protein in an aqueous solution;

c) adding the organic solvent in step a) to the aqueous solution in step b);

d) removing the organic solvent;

to form a pharmaceutical composition where greater than 98% of the therapeutically-active compound is non-covalently bound to the plasma protein.

58. (previously presented) The pharmaceutical composition of claim 57 where the therapeutically-active compound is a cytostatic, an antibiotic, a vitamin, an antiinflammatory, an analgesic, an anticonvulsant, an immunosuppressant, an antiepileptic, an anxiolytic, a hypnotic, an antifungal agent, an anticoagulant, a lipid

peroxidase inhibitor, a coronary vasodilator, an antiarrythmic agent, a cardiotonic, a uricosuric, an antithrombotic, a steroid hormone, or a photo-sensitizer.

59. (previously presented) The pharmaceutical composition of claim 57 where the therapeutically-active compound is amphotericin B, an adriamicine analogue, apazone, azathioprin, bromazepam, camptothecin, carbamazepin, clonazepam, cyclosporin A, diazepam, dicumarol, digitoxin, dipyridamole, disopyramide, flunitrazepam, gemfibrozil, ketochlorin, ketoconazole, miconazole, niflumic acid, oxazepam, paclitaxel, phenobarbital, phenytoin, progesterone, propofol, ritonavir, sulfinpyrazone, suprofene, tacrolimus, tamoxifen, taxonoid, testosterone, tirilazad, trioxsalen, valproic acid, or warfarin.

60. (previously presented) The pharmaceutical composition of claim 57 where the plasma protein is a serum albumin, an immunoglobulin, a glycoprotein, an interferon, or an interleukin.

61-66. (canceled)